Why an FDA Panel Had Concerns About Merck's COVID-19 Pill

An advisory committee to the U.S. Food and Drug Administration (FDA) recently met to review the Emergency Use Authorization (EUA) submission for Merck's (NYSE: MRK) oral COVID-19 therapy, molnupiravir. Although the committee gave a positive recommendation, the vote was very close. In this Motley Fool Live video recorded on Dec. 1, Motley Fool contributors Keith Speights and Brian Orelli discuss why the FDA panel had some concerns about Merck's COVID-19 pill.

Continue reading

Source Fool.com